WO2023213385A1 - Novel biocompatible ta-nb-ti alloys, method for preparing the same, and uses thereof - Google Patents
Novel biocompatible ta-nb-ti alloys, method for preparing the same, and uses thereof Download PDFInfo
- Publication number
- WO2023213385A1 WO2023213385A1 PCT/EP2022/061886 EP2022061886W WO2023213385A1 WO 2023213385 A1 WO2023213385 A1 WO 2023213385A1 EP 2022061886 W EP2022061886 W EP 2022061886W WO 2023213385 A1 WO2023213385 A1 WO 2023213385A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alloy
- biocompatible alloy
- coating
- biocompatible
- prosthesis
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 31
- 229910001069 Ti alloy Inorganic materials 0.000 title description 4
- 229910045601 alloy Inorganic materials 0.000 claims abstract description 150
- 239000000956 alloy Substances 0.000 claims abstract description 150
- 229910020012 Nb—Ti Inorganic materials 0.000 claims abstract description 29
- 239000000463 material Substances 0.000 claims description 98
- 239000011248 coating agent Substances 0.000 claims description 43
- 238000000576 coating method Methods 0.000 claims description 43
- 230000000844 anti-bacterial effect Effects 0.000 claims description 37
- 241000894006 Bacteria Species 0.000 claims description 35
- 239000007943 implant Substances 0.000 claims description 34
- 208000037099 Prosthesis Failure Diseases 0.000 claims description 27
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 24
- 230000003510 anti-fibrotic effect Effects 0.000 claims description 23
- 239000000758 substrate Substances 0.000 claims description 21
- 239000013590 bulk material Substances 0.000 claims description 20
- 230000002829 reductive effect Effects 0.000 claims description 19
- 230000008569 process Effects 0.000 claims description 14
- 210000000988 bone and bone Anatomy 0.000 claims description 13
- 230000002401 inhibitory effect Effects 0.000 claims description 12
- 230000000670 limiting effect Effects 0.000 claims description 12
- 229910052758 niobium Inorganic materials 0.000 claims description 12
- 229910052715 tantalum Inorganic materials 0.000 claims description 12
- 229910052719 titanium Inorganic materials 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 229910052751 metal Inorganic materials 0.000 claims description 9
- 238000002844 melting Methods 0.000 claims description 7
- 239000002184 metal Substances 0.000 claims description 7
- 239000000843 powder Substances 0.000 claims description 7
- 150000001875 compounds Chemical class 0.000 claims description 5
- 150000004678 hydrides Chemical class 0.000 claims description 5
- 239000007858 starting material Substances 0.000 claims description 5
- 230000006378 damage Effects 0.000 claims description 4
- 229910052720 vanadium Inorganic materials 0.000 claims description 4
- 229910052727 yttrium Inorganic materials 0.000 claims description 4
- 229910000791 Oxinium Inorganic materials 0.000 claims description 3
- 239000000654 additive Substances 0.000 claims description 3
- 230000000996 additive effect Effects 0.000 claims description 3
- 229910052782 aluminium Inorganic materials 0.000 claims description 3
- 229910052804 chromium Inorganic materials 0.000 claims description 3
- 229910052737 gold Inorganic materials 0.000 claims description 3
- 239000011261 inert gas Substances 0.000 claims description 3
- 229910052742 iron Inorganic materials 0.000 claims description 3
- 229910052748 manganese Inorganic materials 0.000 claims description 3
- 238000005551 mechanical alloying Methods 0.000 claims description 3
- 238000003701 mechanical milling Methods 0.000 claims description 3
- 230000008018 melting Effects 0.000 claims description 3
- 229910052750 molybdenum Inorganic materials 0.000 claims description 3
- 229910052697 platinum Inorganic materials 0.000 claims description 3
- 229910052709 silver Inorganic materials 0.000 claims description 3
- 238000005245 sintering Methods 0.000 claims description 3
- 229910052721 tungsten Inorganic materials 0.000 claims description 3
- 229910052726 zirconium Inorganic materials 0.000 claims description 3
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 claims description 2
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 claims description 2
- 229910052796 boron Inorganic materials 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- 229910052735 hafnium Inorganic materials 0.000 claims description 2
- 238000010438 heat treatment Methods 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 150000001247 metal acetylides Chemical class 0.000 claims description 2
- 150000004767 nitrides Chemical class 0.000 claims description 2
- 229910052757 nitrogen Inorganic materials 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 229910021332 silicide Inorganic materials 0.000 claims description 2
- 229910052718 tin Inorganic materials 0.000 claims description 2
- RUDFQVOCFDJEEF-UHFFFAOYSA-N yttrium(III) oxide Inorganic materials [O-2].[O-2].[O-2].[Y+3].[Y+3] RUDFQVOCFDJEEF-UHFFFAOYSA-N 0.000 claims description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims 2
- MCMNRKCIXSYSNV-UHFFFAOYSA-N Zirconium dioxide Chemical compound O=[Zr]=O MCMNRKCIXSYSNV-UHFFFAOYSA-N 0.000 claims 2
- 229910034327 TiC Inorganic materials 0.000 claims 1
- CJNBYAVZURUTKZ-UHFFFAOYSA-N hafnium(IV) oxide Inorganic materials O=[Hf]=O CJNBYAVZURUTKZ-UHFFFAOYSA-N 0.000 claims 1
- 229910000048 titanium hydride Inorganic materials 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 22
- 239000010955 niobium Substances 0.000 description 15
- 239000010936 titanium Substances 0.000 description 15
- 230000014509 gene expression Effects 0.000 description 11
- KPKZJLCSROULON-QKGLWVMZSA-N Phalloidin Chemical compound N1C(=O)[C@@H]([C@@H](O)C)NC(=O)[C@H](C)NC(=O)[C@H](C[C@@](C)(O)CO)NC(=O)[C@H](C2)NC(=O)[C@H](C)NC(=O)[C@@H]3C[C@H](O)CN3C(=O)[C@@H]1CSC1=C2C2=CC=CC=C2N1 KPKZJLCSROULON-QKGLWVMZSA-N 0.000 description 10
- 244000005700 microbiome Species 0.000 description 10
- 206010016654 Fibrosis Diseases 0.000 description 8
- 206010061218 Inflammation Diseases 0.000 description 8
- 230000004761 fibrosis Effects 0.000 description 8
- 230000004054 inflammatory process Effects 0.000 description 8
- 230000000845 anti-microbial effect Effects 0.000 description 7
- 230000002757 inflammatory effect Effects 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 5
- 108010009711 Phalloidine Proteins 0.000 description 5
- 241001147736 Staphylococcus capitis Species 0.000 description 5
- 239000012620 biological material Substances 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 4
- 238000003618 dip coating Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000003176 fibrotic effect Effects 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 210000000963 osteoblast Anatomy 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 229920002477 rna polymer Polymers 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 238000005507 spraying Methods 0.000 description 4
- 239000010409 thin film Substances 0.000 description 4
- 102000016359 Fibronectins Human genes 0.000 description 3
- 108010067306 Fibronectins Proteins 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 108090001005 Interleukin-6 Proteins 0.000 description 3
- 102000004889 Interleukin-6 Human genes 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000007797 corrosion Effects 0.000 description 3
- 238000005260 corrosion Methods 0.000 description 3
- 210000000805 cytoplasm Anatomy 0.000 description 3
- 210000004292 cytoskeleton Anatomy 0.000 description 3
- 239000004053 dental implant Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 210000001624 hip Anatomy 0.000 description 3
- 210000004394 hip joint Anatomy 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- 230000028709 inflammatory response Effects 0.000 description 3
- 210000003127 knee Anatomy 0.000 description 3
- 210000000629 knee joint Anatomy 0.000 description 3
- 210000001616 monocyte Anatomy 0.000 description 3
- 238000003757 reverse transcription PCR Methods 0.000 description 3
- 230000037390 scarring Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000001974 tryptic soy broth Substances 0.000 description 3
- 108010050327 trypticase-soy broth Proteins 0.000 description 3
- 239000012103 Alexa Fluor 488 Substances 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 206010017533 Fungal infection Diseases 0.000 description 2
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- 101001066129 Homo sapiens Glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 102000000589 Interleukin-1 Human genes 0.000 description 2
- 208000031888 Mycoses Diseases 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 description 2
- 238000002441 X-ray diffraction Methods 0.000 description 2
- 230000002300 anti-fibrosis Effects 0.000 description 2
- 239000012237 artificial material Substances 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 239000003519 biomedical and dental material Substances 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 229910052729 chemical element Inorganic materials 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 238000002149 energy-dispersive X-ray emission spectroscopy Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 102000047486 human GAPDH Human genes 0.000 description 2
- 229940116886 human interleukin-6 Drugs 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000009434 installation Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 238000001543 one-way ANOVA Methods 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000010200 validation analysis Methods 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 206010000871 Acute monocytic leukaemia Diseases 0.000 description 1
- 241000203069 Archaea Species 0.000 description 1
- 229910052684 Cerium Inorganic materials 0.000 description 1
- 208000029767 Congenital, Hereditary, and Neonatal Diseases and Abnormalities Diseases 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 229910052692 Dysprosium Inorganic materials 0.000 description 1
- 229910052691 Erbium Inorganic materials 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 229910052693 Europium Inorganic materials 0.000 description 1
- 238000001135 Friedman test Methods 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 229910052688 Gadolinium Inorganic materials 0.000 description 1
- 229910052689 Holmium Inorganic materials 0.000 description 1
- 229910052765 Lutetium Inorganic materials 0.000 description 1
- 208000035489 Monocytic Acute Leukemia Diseases 0.000 description 1
- 229910001257 Nb alloy Inorganic materials 0.000 description 1
- 229910052779 Neodymium Inorganic materials 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 229910052777 Praseodymium Inorganic materials 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 229910052772 Samarium Inorganic materials 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229910052771 Terbium Inorganic materials 0.000 description 1
- 229910052775 Thulium Inorganic materials 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 206010054094 Tumour necrosis Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229910052769 Ytterbium Inorganic materials 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 238000005275 alloying Methods 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 238000011882 arthroplasty Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000010065 bacterial adhesion Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000032770 biofilm formation Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 238000007675 cardiac surgery Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000002389 environmental scanning electron microscopy Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 229910052746 lanthanum Inorganic materials 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 238000003754 machining Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000013160 medical therapy Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 238000009862 microstructural analysis Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- GUCVJGMIXFAOAE-UHFFFAOYSA-N niobium atom Chemical compound [Nb] GUCVJGMIXFAOAE-UHFFFAOYSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 208000024335 physical disease Diseases 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 238000010149 post-hoc-test Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000003870 refractory metal Substances 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229910052706 scandium Inorganic materials 0.000 description 1
- 238000004626 scanning electron microscopy Methods 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 239000012192 staining solution Substances 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 230000003746 surface roughness Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- GUVRBAGPIYLISA-UHFFFAOYSA-N tantalum atom Chemical compound [Ta] GUVRBAGPIYLISA-UHFFFAOYSA-N 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000007838 tissue remodeling Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- GPPXJZIENCGNKB-UHFFFAOYSA-N vanadium Chemical compound [V]#[V] GPPXJZIENCGNKB-UHFFFAOYSA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/02—Inorganic materials
- A61L27/04—Metals or alloys
- A61L27/047—Other specific metals or alloys not covered by A61L27/042 - A61L27/045 or A61L27/06
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/02—Inorganic materials
- A61L31/022—Metals or alloys
-
- C—CHEMISTRY; METALLURGY
- C22—METALLURGY; FERROUS OR NON-FERROUS ALLOYS; TREATMENT OF ALLOYS OR NON-FERROUS METALS
- C22C—ALLOYS
- C22C14/00—Alloys based on titanium
-
- C—CHEMISTRY; METALLURGY
- C22—METALLURGY; FERROUS OR NON-FERROUS ALLOYS; TREATMENT OF ALLOYS OR NON-FERROUS METALS
- C22C—ALLOYS
- C22C27/00—Alloys based on rhenium or a refractory metal not mentioned in groups C22C14/00 or C22C16/00
- C22C27/02—Alloys based on vanadium, niobium, or tantalum
-
- C—CHEMISTRY; METALLURGY
- C22—METALLURGY; FERROUS OR NON-FERROUS ALLOYS; TREATMENT OF ALLOYS OR NON-FERROUS METALS
- C22C—ALLOYS
- C22C30/00—Alloys containing less than 50% by weight of each constituent
Definitions
- the present invention relates to novel biocompatible Ta-Nb-Ti alloys, methods for preparing the same, and uses thereof.
- Titanium (Ti) or titanium alloys (z.B. Ti-6A1-4V), are the material most frequently used in dental implants, orthopedic implants, prostheses, and vascular stents because of their outstanding physical and biological properties, such as low density, excellent mechanical strength, corrosion resistance (prevention of corrosive damage to the implant), and biocompatibility (no tissue damage by the implant material or by corrosive/abrasive particles).
- titanium or titanium alloys are prime factors governing bone integration.
- the mechanisms of the superior biocompatibility of titanium and titanium alloys are presently unknown and implants composed thereof or coated therewith still provoke a significant inflammatory response.
- Ta tantalum
- Nb niobium
- Ta is used for suture wires, wire meshes, and nets, as well as skull implants. It is particularly corrosion-resistant and supports the in-growth of bone structures into the implant structures.
- Nb is used as OXINIUM® alloy in knee implants, and there are studies showing that Nb as a component has better bio-compatibility than cobalt, nickel, or vanadium, for example.
- HSAs modem material class multi-component high-entropy alloys
- RHEAs refractory metal-based high-entropy alloys
- the present invention is based on the surprising finding that novel Ta-Nb-Ti alloys show superior biocompatibility such as a markedly reduced inflammatory capacity, and, in addition, have an anti-bacterial and anti-fibrosis effect, which makes them particularly suitable for use as a biomedical material, e.g. for medical devices such as implants or prostheses.
- the invention relates to a material composed of or coated with the inventive biocompatible alloy.
- the invention relates to a material composed of or coated with the inventive biocompatible alloy for use as a material with anti-bacterial and/or anti-inflammatory effects.
- the invention relates to a material composed of or coated with the inventive biocompatible alloy for use as a material with an anti-fibrotic effect.
- the invention relates to a material composed of or coated with the inventive biocompatible alloy for use as a material for prostheses with reduced or no septic prosthesis loosening.
- the present invention relates to a coating comprising the inventive biocompatible alloy.
- the invention relates to the use of the inventive biocompatible alloy as a coating.
- the invention relates to the inventive biocompatible alloy for use as coating or substrate/bulk material with anti-bacterial and/or anti-inflammatory effects.
- the present invention relates to the inventive biocompatible alloy for use as coating or substrate/bulk material with an anti-fibrotic effect.
- the present invention relates to the inventive biocompatible alloy for use as coating or substrate/bulk material for prostheses with reduced or no septic prosthesis loosening.
- the present invention relates to the use of the inventive biocompatible alloy as coating or substrate/bulk material with anti-bacterial and/or anti-inflammatory effects.
- the present invention relates to the use of the inventive biocompatible alloy as coating or substrate/bulk material with an anti-fibrotic effect.
- the present invention relates to the use of the inventive biocompatible alloy as coating or substrate/bulk material for prostheses with reduced or no septic prosthesis loosening.
- the present invention relates to the use of a material composed of or coated with the inventive biocompatible alloy as a material with anti-bacterial and/or antiinflammatory effects.
- the present invention relates to the use of a material composed of or coated with the inventive biocompatible alloy as a material with an anti-fibrotic effect.
- the present invention relates to the use of a material composed of or coated with the inventive biocompatible alloy as a material for prostheses with reduced or no septic prosthesis loosening.
- the present invention relates to a method for the manufacture of an inventive biocompatible alloy, wherein the process comprises melting/remelting or mechanical milling/alloying elemental Ti, Nb, Ta, and/or hydrides of the respective elements as well as partially or entirely pre-alloyed starting materials in the respective relative amounts in an arc-melting device under an Ar atmosphere, in a powder mill/attrition device under inert gas atmosphere and/or subsequent sintering processes and/or fabricated by additive or generative manufacturing methods.
- the present invention relates to a method for treating bone damages comprising implanting a material composed of or coated with the inventive biocompatible alloy.
- the present invention relates to a method for treating septic prosthesis loosening comprising implanting a prosthesis composed of or coated with the inventive biocompatible alloy.
- the terms “consisting essentially of' or “comprising substantially” mean that specific further components can be present, namely those not materially affecting the essential characteristics of the compound or composition, e.g., unavoidable impurities.
- biocompatible refers to the ability of a biomaterial to perform its desired function for medical therapy, without eliciting any undesirable local or systemic effects in the recipient or beneficiary of that therapy, but generating the most appropriate beneficial cellular or tissue response in that specific situation, and optimizing the clinically relevant performance of that therapy.
- alloy refers to a mixture of chemical elements of which at least one is a metal. Unlike chemical compounds with metallic bases, an alloy will retain all the properties of a metal in the resulting material, such as electrical conductivity, ductility, opacity, and luster, but may have properties that differ from those of the pure metals, such as increased strength or hardness. In some cases, an alloy may reduce the overall cost of the material while preserving important properties. In other cases, the mixture imparts synergistic properties to the constituent metal elements such as corrosion resistance or mechanical strength.
- rare earths refers to the elements Sc, Y, La, Ce, Pr, Nd, Pm, Sm, Eu, Gd, Tb, Dy, Ho, Er, Tm, Yb, and Lu.
- atomic percent refers to the number of atoms of an element in 100 atoms representative of a substance.
- interstitially solvable elements refers to elements that are completely or partially soluble in the metal lattice of an alloy.
- equivalent alloy refers to an alloy where the metallic elements are present in equal atomic percentages.
- medical device refers to a non-naturally occurring object or artificial object that is used to examine and/or treat a subject, that is inserted or implanted in a subject, or that is applied to a surface of a subject.
- An implantable device is one intended to be completely imbedded in the body without any structure left outside the body (e.g. an implant or a prothesis).
- An insertable device is one that is partially imbedded in the body but has a part intended to be external (e g. a catheter or a drain). Medical devices can be intended for shortterm or long-term residence where they are positioned.
- a hip implant is intended for several years of use, for example.
- a tissue expander may only be needed for a few months, and is removed thereafter. Insertable devices tend to remain in place for shorter times than implantable devices, in part because they come into more contact with microorganisms that can colonize them.
- the medical devices described herein are composed of or are coated with the biocompatible alloy of the present invention. Said alloy has an anti-bacterial and/or anti-inflammatory effect. Thus, the medical device has a longer life time and can remain longer in the subject’s body.
- the subject described herein may be a human or an animal.
- the medical device may be an extracorporeal medical device, an implant, preferably a prothesis, or a catheter.
- Extracorporeal medical device refers to device whose function is performed outside the body. Extracorporeal devices are the artificial organs that remain outside the body while treating a patient. Extracorporeal devices are useful, for example, in hemodialysis and cardiac surgery.
- implant refers to an artificial material intended for placement in a human or animal body.
- implant refers to an artificial material implanted in the body to remain there permanently or at least for a longer period of time.
- implant can be applied to the entire spectrum of medical devices intended for placement in a human or animal body.
- the implant is preferably a prosthesis.
- prosthesis refers to a medical device that replaces a missing body part, which may be lost through trauma, disease, or a condition present at birth (congenital disorder). A prosthesis is intended to restore the normal functions of the missing body part. A “prosthesis” can also be designated as prosthetic implant.
- the prosthesis is an endoprosthesis.
- endoprosthesis from the Greek endo “inside” refers to a joint replacement. It remains permanently in the body and replaces a damaged joint in whole or in part.
- An endoprosthesis which replaces a damaged joint in whole is designated as total endoprosthesis and an endoprosthesis which replaces a damaged joint in part is designated as partial endoprosthesis.
- the endoprosthesis is a hip joint or a knee joint.
- the surgical procedure for replacing the joint with a prosthesis is called arthroplasty.
- coating refers to any layer covering a surface, e g. of a material or article such as medical device.
- the inventive biocompatible alloy is used for coating or as coating.
- the biocompatible alloy to be coated can be in form of a liquid, a paste, a semi-solid, or a solid. It is preferred that the coating completely and/or uniformly covers the surface of the material to be coated.
- the coating has preferably a thickness of between 1 nm and 1000 pm, preferably 40 nm and 50 pm, more preferably between 0.1 pm and 10 pm and most preferably between 0.5 pm and 5 pm
- the coating can be achieved by dip coating and/or spray coating, as well as thin- film technology processes (such as CVD, PVD) and powder pack cementation.
- Medical devices such as implants or prostheses, are widely used to replace damaged tissues or to treat various diseases. However, they may cause microbial infections such as bacterial or fungal infections, when introduced into the body of a subject.
- the inventive alloy as described herein has an anti-microbial effect or activity, specifically a growth-limiting/inhibiting effect on microorganisms.
- the microorganisms are preferably selected from the group consisting of bacteria, viruses, archaea, fungi and protists.
- anti-microbial effect or activity of a material, as used herein, is associated with the property of the material to kill or inhibit microorganisms. Particularly, the inhibition of microorganisms is achieved by slow down the rate of growth of the microorganisms.
- anti-microbial activity or effect can also be defined as a collective term for all active principles that inhibit the growth of microorganisms, prevent the formation of colonies of microorganisms, and may destroy microorganisms.
- the material may be a material composed of or coated with the inventive alloy as described herein.
- the inventive alloy as described herein has an anti-bacterial effect or activity, specifically a growth-limiting/inhibiting effect or activity on bacteria.
- anti-bacterial effect or activity of a material, as used herein, is associated with the property of the material to kill or inhibit bacteria. Particularly, the inhibition of bacteria is achieved by slow down the rate of growth of the bacteria.
- anti-bacterial activity or effect can also be defined as a collective term for all active principles that inhibit the growth of bacteria, prevent the formation of colonies of bacteria, and may destroy bacteria.
- the material may be a material composed of or coated with the inventive alloy as described herein.
- microorganisms such as bacteria may be inhibited by the material composed of or coated with the inventive alloy by at least 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 98% or 99%, or by 100% as compared to a material not being composed or coated with the inventive alloy.
- bacteria growth is inhibited by at least 20%. More preferably, bacteria growth is inhibited by at least 40%. Even more preferably, bacteria growth is inhibited by at least 60%. Most preferably, bacteria growth is inhibited by at least 90% or of even 100%.
- inventive alloy prevents or does not cause an inflammatory response in the body of a subject.
- anti-inflammatory effect or activity of a material, as used herein, is associated with the property of the material to reduce inflammation (such as redness, swelling, and/or pain) in the body.
- An anti-inflammatory material is able to block certain substances in the body that cause inflammation or that does not cause inflammation due to its own composition/structure.
- the material may be a material composed of or coated with the inventive alloy as described herein.
- medical devices such as implants or prostheses
- implants or prostheses are widely used to replace damaged tissues or to treat various diseases.
- they may lead to an increased fibrosis when introduced into the body of a subject.
- the increased fibrosis is associated with a subsequent restriction of the range of motion of the affected medical devices, e g. joints.
- the inventive alloy as described herein has an anti-fibrotic effect. In this way, movement restrictions after implantation of a medical device can be prevented.
- Fibrotic and scarring processes are mainly derived by the proliferation of fibroblasts and exuberant extracellular matrix (ECM) expression.
- ECM extracellular matrix
- anti-fibrotic effect or activity of a material, as used herein, is associated with the property to prevent such fibrotic and scarring processes in the body.
- the material may be a material composed of or coated with the inventive alloy as described herein.
- prosthesis coating for example, a prothesis loosening can be reduced or inhibited.
- prosthesis loosening can be reduced or inhibited with the inventive alloy as a coating by at least 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 98% or 99%, or by 100% as compared to a prosthesis not coated with the inventive alloy.
- prosthesis loosening is inhibited by at least 20%. More preferably, prosthesis loosening is inhibited by at least 40%. Even more preferably, prosthesis loosening is inhibited by at least 60%. Most preferably, prosthesis loosening is inhibited by at least 90% or of even 100%.
- substrate/bulk material refers to the alloy and or the coating in a compact state after processing.
- the present invention is based on the surprising finding that novel Ta-Nb-Ti alloys show superior biocompatibility such as a markedly reduced inflammatory capacity, and, in addition, have an anti-bacterial and anti-fibrosis effect, which makes them particularly suitable for use as a biomedical material, e.g. for implants or prostheses.
- the present invention relates to a biocompatible alloy
- the biocompatible alloy may be selected from the group consisting of Ta-Nb-Ti, Ta-Nb-lOTi, Ta-Nb-50Ti, Ta-Nb-70Ti, Ta-Nb-Ti- 6.2Co, Ta-Nb-Ti-6.2Cr, Ta-Nb-Ti-2.2Co-2.2Cr, Ta-Nb-Ti-Hf, Hf-Nb-Ti, Ta-Nb-Ti-Zr, Hf-Nb- Ti-Zr, and Ta-Nb-Ti-Hf-Zr, wherein the relative amounts of each element preferably vary by no more than ⁇ 15 atomic %, e.g.
- the biocompatible alloy additionally comprises one or more compounds or combinations selected from the group consisting of oxides, nitrides, borides, silicides, hydrides, and carbides, in particular AI2O3, ZrCh, TiCh, Y2O3, HfCh, TiN, Cas[OH
- the biocompatible alloy additionally comprises one or more interstitially solvable elements selected from the group consisting of C, O, N, H, and B; wherein the relative amounts of each element in each particular phase are maximum 2 atomic %, e.g. 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, or 2 atomic %.
- biocompatible alloys of the present invention have anti-bacterial and/or anti-inflammatory and/or anti-fibrotic effects and/or reduce or prevent septic prosthesis loosening.
- the anti-bacterial effects preferably comprise a growth-limiting/inhibiting effect on bacteria.
- the anti-inflammatory effects comprise reducing or preventing inflammation in the body or body parts, resulting, e.g., in redness, swelling, and pain.
- the anti-fibrotic effects comprise reducing or preventing fibrosis, also known as fibrotic scarring, i.e., a pathological wound healing in which connective tissue replaces normal parenchymal tissue to the extent that it goes unchecked, leading to considerable tissue remodeling and the formation of permanent scar tissue.
- fibrotic scarring also known as fibrotic scarring
- the present invention relates to a material or an article composed of or coated with the inventive biocompatible alloy.
- the coating completely and/or uniformly covers the surface of the material or article to be coated.
- the coating has preferably a thickness of between 1 nm and 1000 pm, preferably 40 nm and 50 pm, more preferably between 0.1 pm and 10 pm and most preferably between 0.5 pm and 5 pm.
- the coating can be achieved by dip coating and/or spray coating, as well as thin-film technology processes (such as CVD, PVD) and powder pack cementation.
- the invention relates to a material or an article composed of or coated with the inventive biocompatible alloy for use as a material or an article with anti-bacterial and/or anti-inflammatory effects.
- the anti-bacterial effects comprise a growth-limiting/inhibiting effect on bacteria.
- bacteria growth may be inhibited by the material or article composed of or coated with the inventive alloy by at least 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 98% or 99%, or by 100% as compared to a material or an article not being composed or coated with the inventive alloy.
- bacteria growth is inhibited by at least 20%. More preferably, bacteria growth is inhibited by at least 40%. Even more preferably, bacteria growth is inhibited by at least 60%. Most preferably, bacteria growth is inhibited by at least 90% or of even 100%.
- the invention relates to a material or article composed of or coated with the inventive biocompatible alloy for use as a material or article with an anti-fibrotic effect.
- the material or article composed of or coated with the inventive biocompatible alloy has anti-bacterial and/or anti-inflammatory and/or anti-fibrotic effects.
- the invention relates to a material or article composed of or coated with the inventive biocompatible alloy for use as a material or article for prostheses with reduced or no septic prosthesis loosening.
- the material or article composed of or coated with the inventive biocompatible alloy as described above is a medical device, e g , an implant (e g., a dental implant), a prosthesis (e.g., a hip or knee prosthesis), a tool, a bone pin, a bone screw, a bone plate, or a container.
- an implant e g., a dental implant
- a prosthesis e.g., a hip or knee prosthesis
- a tool e.g., a bone pin, a bone screw, a bone plate, or a container.
- prosthesis loosening to mean that an endoprosthesis (also known as an implant), for example, the components of an artificial hip joint or knee joint, are no longer firmly anchored in the bone.
- Prosthesis loosening is a phenomenon that occurs in approximately 8% of all implanted joint prostheses within 10 years of installation. This affects approximately 10,000 to 12,000 patients per year worldwide.
- the present invention relates a coating comprising the inventive biocompatible alloy.
- the coating has preferably a thickness of between 1 nm and 1000 pm, preferably 40 nm and 50 pm, more preferably between 0.1 pm and 10 pm and most preferably between 0.5 pm and 5 pm.
- the coating can be achieved by dip coating and/or spray coating, as well as thin-film technology processes (such as CVD, PVD) and powder pack cementation.
- the coating may be applied onto a material (e g. medical device) or article.
- the present invention relates to the use of the inventive biocompatible alloy as a coating or substrate/bulk material.
- the biocompatible alloy to be coated can be in form of a liquid, a paste, a semi-solid, or a solid. It is preferred that the coating completely and/or uniformly covers the surface of the material to be coated.
- the coating has preferably a thickness of between 1 nm and 1000 pm, preferably 40 nm and 50 pm, more preferably between 0.1 pm and 10 pm and most preferably between 0.5 pm and 5 m.
- the coating can be achieved by dip coating and/or spray coating, as well as thin-film technology processes (such as CVD, PVD) and powder pack cementation.
- the coating may be applied onto a material (e g. medical device) or article.
- the invention relates to the inventive biocompatible alloy for use as coating or substrate/bulk material with anti-bacterial and/or anti-inflammatory effects.
- the anti-bacterial effects comprise a growth-limiting/inhibiting effect on bacteria.
- the present invention relates to the inventive biocompatible alloy for use as coating or substrate/bulk material with an anti-fibrotic effect.
- the present invention relates to the inventive biocompatible alloy for use as coating or substrate/bulk material for prostheses with reduced or no septic prosthesis loosening.
- the present invention relates to the use of the inventive biocompatible alloy as coating or substrate/bulk material with anti-bacterial and/or anti-inflammatory effects.
- the anti-bacterial effects comprise a growth-limiting/inhibiting effect on bacteria.
- the present invention relates to the use of the inventive biocompatible alloy as coating or substrate/bulk material with an anti-fibrotic effect.
- the present invention relates to the use of the inventive biocompatible alloy as coating or substrate/bulk material for prostheses with reduced or no septic prosthesis loosening.
- the present invention relates to the use of a material or an article composed of or coated with the inventive biocompatible alloy as a material or an article with anti-bacterial and/or anti-inflammatory effects.
- the anti-bacterial effects comprise a growth-limiting/inhibiting effect on bacteria.
- the present invention relates to the use of a material or an article composed of or coated with the inventive biocompatible alloy as a material or an article with an anti-fibrotic effect.
- the present invention relates to the use of a material or an article composed of or coated with the inventive biocompatible alloy as a material or an article for prostheses with reduced or no septic prosthesis loosening.
- the material or article composed of or coated with the inventive biocompatible alloy as described above is a medical device, e.g., an implant (e.g., a dental implant), a prosthesis (e.g., a hip or knee prosthesis), a tool, a bone pin, a bone screw, a bone plate, or a container.
- a medical device e.g., an implant (e.g., a dental implant), a prosthesis (e.g., a hip or knee prosthesis), a tool, a bone pin, a bone screw, a bone plate, or a container.
- the material or article composed of or coated with the inventive biocompatible alloy has anti-bacterial and/or anti-inflammatory and/or anti-fibrotic effects.
- the anti-bacterial and anti-fibrotic effects of the inventive alloys reduce or prevent septic prosthesis loosening.
- prosthesis loosening to mean that an endoprosthesis (also known as an implant), for example, the components of an artificial hip joint or knee joint, are no longer firmly anchored in the bone.
- Prosthesis loosening is a phenomenon that occurs in approximately 8% of all implanted joint prostheses within 10 years of installation. This affects approximately 10,000 to 12,000 patients per year worldwide.
- the present invention relates to a method for the manufacture of the inventive biocompatible alloy, wherein the process comprises melting/remelting or mechanical milling/alloying elemental Ti, Nb, Ta, and/or hydrides of the respective elements as well as partially or entirely pre-alloyed starting materials in the respective relative amounts in an arc-melting device under an Ar atmosphere, in a powder mill/attrition device under inert gas atmosphere and/or subsequent sintering processes and/or fabricated by additive or generative manufacturing methods.
- the inventive biocompatible alloy As to the preferred embodiments of the inventive biocompatible alloy, it is referred to the first aspect of the present invention.
- a subsequent heat treatment is used, e g. to ensure sufficient homogeneity of the alloy.
- the present invention relates to a method for treating bone damages comprising implanting a material composed of or coated with the inventive biocompatible alloy.
- the present invention relates to a method for treating septic prosthesis loosening comprising implanting a prosthesis composed of or coated with the inventive biocompatible alloy.
- FIGURE 1 shows the calculation of nucleus to cytoplasm ratio for the tested alloys for validation of the osteoblast attachment to alloy surfaces.
- FIGURE 2 shows the expression of inflammatory and fibrosis marker genes by monocytes incubated on the novel biocompatible alloy Ta-Nb-Ti, compared to standard implant materials data and elemental Ta and Nb.
- FIGURE 3 shows the anti-bacterial effects of the novel biocompatible Ta-Nb-Ti alloy in comparison to the pure components of the alloy and other alloys used as biomaterials.
- the produced oblong-shaped (due to the use of an elongated mold) melted product was cut into 2mm thick slices by means of electric discharge machining (EDM).
- EDM electric discharge machining
- One slice was used for microstructural analysis and thus metallographically prepared (ground with SiC paper to 1000 grit, polished using 3 pm and 1 pm diamond suspension, and finished using colloidal silica suspension subsequently) afterward.
- the remaining slices were cleaned from the EDM-burr and ground to a defined grit size of 1200.
- X-ray diffraction analysis was performed on a X’Pert Pro (PANalytical, Almelo, The Netherlands), using Co Ka radiation.
- Microstructural observations were carried out using scanning electron microscopy (ESEM XL30 FEG, FEI, Hillsboro, OR, USA), using back-scattered electron (BSE) imaging with the following setup: Centaurus BSE detector with an acceleration voltage of 25 kV, magnification of lOOx and a working distance of 11.4 mm.
- the surface roughness of the samples was analyzed by using a confocal microscope (psurf expert, NanoFocus AG, Oberhausen, Germany) on a surface area of 322 x 321 pm, using a 20x magnification objective with a lateral (x, y) measuring range of 800 pm.
- the contact angles of the surfaces were determined using an optical contact angle and drop contour analyzer (OCA 20, DataPhysics Instruments GmbH, Filderstadt, Germany) and the corresponding software (SCA 20, DataPhysics Instruments GmbH, Filderstadt, Germany).
- microhardness analysis was carried out using 20 HVO.1 indents in a square grid across the entire sample surface, using an automatic hardness tester VH3300 (Wilson/Buehler, Esslingen, Germany).
- SaOs-2 cells were seeded with a cell number of 0.3 x 10 5 inlOO uL for 2 h on platelets of standard implant alloys (Co-28Cr-6Mo, Ti-6A1-4V, and pure Ti), elemental Ta and Nb, and novel biocompatible alloy Ta-Nb-Ti to let the cells attach to the surface. Afterward, 1 mL DMEM (Dulbecco Modified Eagle Medium) culture medium with the addition of 10% FCS (fetal calf serum) and 1% penicillin/ streptomycin was pipetted into each well to cover the platelets with cells.
- DMEM Dynamic Eagle Medium
- the cells were fixed with 4% formaldehyde and washed three times with PBS (phosphate-buffered saline).
- PBS phosphate-buffered saline
- the samples were incubated with 200 pL of PBS with Phalloidin Alexa Fluor 488 (1 : 100) and DAPI (4 F ,6-Diamidino-2-phenylindol) (1:1000) in the dark for 15 min (room temperature, RT). Excess staining solution was removed by washing three times with PBS. The samples were stored at 4 °C in the dark until further use.
- Imaging was performed with a Zeiss fluorescence microscope (Axio Observer.Zl, Zeiss, Jena, Germany) at 63 Ox magnification. Fluorescence was detected at the wavelengths 488 nm (Phalloidin green) and 454 nm (DAPI blue). Four images were taken of each sample. For evaluation, the area of one cell (green fluorescence) was divided by the size of the nucleus (blue fluorescence) using ImageJ.
- Mona-mac-6 cells are a human acute monocytic leukemia derived cell line. These cells were cultured at a density 0.5 x 10 6 in 100 pL on the different alloy specimens for 24 h. Subsequently, the cells were lysed using TRIZol, and RNA (ribonucleic acid) was isolated for quantitative RT-PCR (reverse transcription polymerase chain reaction).
- hIL-ip human interleukin- 1 P
- hTNF-a human tumor necrosis factor-oc
- hIL-6 human interleukin-6
- hGAPDH human glyceralde- hyde-3 -phosphate dehydrogenase
- FiGURE 2 shows the expression of inflammatory marker genes (IL-6, IL-ip, TNF-ot) and fibrosis marker genes (TGF-P, fibronectin) by monocytes incubated on novel biocompatible alloy Ta-Nb-Ti, compared to standard implant materials data and elemental Ta and Nb.
- GAPDH was used as housekeeping. The values are given as mean with SEM and were analyzed for statistical significance using a one-way ANOVA with Dunn's post-hoc test.
- the novel alloy Ta-Nb-Ti is comparable with the reference samples and thus showed no negative influence of the alloy composition.
- the novel alloy Ta-Nb-Ti showed a significantly lower value than the reference samples, which indicates an anti-inflammatory effect of the alloy.
- S. capitis (DSM 20326 (from Leibniz Institute DSMZ) was cultivated overnight in tryptic Soy Broth (TSB). The following day 1 ml TSB was inoculated with a 1 : 100 dilution of the S. captitis overnight culture with an optical density of 1 at 600 nm (OD600) for 24 hours. The medium was removed and washed twice with PBS and subsequently fixed with 4 % paraformaldehyde for 30 min at room temperature. The samples were incubated with 1 ml PBS and 4', 6- diamidine-2-phenylindole (DAPI 1 : 1000) to visualize the adhering bacteria on the surface.
- DAPI 1 6- diamidine-2-phenylindole
- the amount of adhering bacteria was quantified in 630x magnification microscopic pictures (Zeiss fluorescence microscope Axio Observer.Zl, Jena, Germany). The fluorescence of the (DAPI) was excited by a wavelength of 454 nm. Pictures from five different areas from each sample were taken and evaluated by counting the amount of bacteria with ImageJ software.
- the key step in biofilm formation on endoprosthetic implant materials is the adhesion of pathogens to the respective material.
- FIGURE 3 shows the anti-bacterial effects of the novel biocompatible Ta-Nb-Ti alloy in comparison to the pure components of the alloy (Ta, Nb, and Ti) and other alloys used as biomaterials (Ti-6A1-4V, CoCrMo).
- S. capitis Staphylococcus capitis
- E coli Escherichia coli. It can be seen that the number of bacteria on the novel Ti-Nb-Ti alloy was many times lower than the number on all other reference samples.
- the Phalloidin is fluorescently labeled with Alexa Fluor 488, which stains the cytoskeleton of the cell green. There is no difference in the number of osteoblasts attached to the different surfaces. Furthermore, the ratio between nucleus and cytoplasm was evaluated to compare the attachment behavior of the cells. Again, there was no difference observed between the alloys tested, indicating no negative effect on the osteoblasts (FIGURE 1).
- a reaction towards a foreign material in the human body is an unavoidable process that takes place whenever any material is implanted. This reaction is mostly inflammatory (e.g., IL- 6 and TNF-a) and can develop into a fibrotic response (TGF-P and fibronectin) over time.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Metallurgy (AREA)
- Mechanical Engineering (AREA)
- Materials Engineering (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Inorganic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Medicinal Chemistry (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
- Heart & Thoracic Surgery (AREA)
- Surgery (AREA)
- Vascular Medicine (AREA)
- Materials For Medical Uses (AREA)
Abstract
The invention relates to novel biocompatible Ta-Nb-Ti alloys, methods for preparing the same, and uses thereof.
Description
NOVEL BIOCOMPATIBLE Ta-Nb-Ti ALLOYS, METHOD FOR PREPARING THE SAME, AND USES THEREOF
The present invention relates to novel biocompatible Ta-Nb-Ti alloys, methods for preparing the same, and uses thereof.
BACKGROUND
Titanium (Ti) or titanium alloys (z.B. Ti-6A1-4V), are the material most frequently used in dental implants, orthopedic implants, prostheses, and vascular stents because of their outstanding physical and biological properties, such as low density, excellent mechanical strength, corrosion resistance (prevention of corrosive damage to the implant), and biocompatibility (no tissue damage by the implant material or by corrosive/abrasive particles).
The surface chemistry and structure of titanium or titanium alloys are prime factors governing bone integration. The mechanisms of the superior biocompatibility of titanium and titanium alloys are presently unknown and implants composed thereof or coated therewith still provoke a significant inflammatory response.
Besides titanium, also tantalum (Ta) and niobium (Nb) are established in medical technology and are used in various applications: Ta is used for suture wires, wire meshes, and nets, as well as skull implants. It is particularly corrosion-resistant and supports the in-growth of bone structures into the implant structures. Nb is used as OXINIUM® alloy in knee implants, and there are studies showing that Nb as a component has better bio-compatibility than cobalt, nickel, or vanadium, for example.
During the last years, the modem material class multi-component high-entropy alloys (HEAs), has gained tremendous attention in the field, which can be attributed to two main reasons.
Firstly, the new concept of combining several elements (at least 5 principal elements with concentrations between 5 and 35 at. %) in contrast to conventional alloys, mostly containing only two or three elements in addition to the main alloy constituent, results in a broad variety of possible combinations, thus leading to completely novel alloys with exceptional properties.
Secondly, recently developed refractory metal-based high-entropy alloys (RHEAs) have shown properties that are superior to those of current state-of-the-art alloys, which are attributed
to several unique thermodynamic effects. However, besides the outstanding mechanical properties, abrasion resistance, and thermal resistance, a vast variety of chemical elements used in RHEAs also belong to the category of biocompatible elements, hence promising to lead to the development of potentially superior biomedical materials.
The present invention is based on the surprising finding that novel Ta-Nb-Ti alloys show superior biocompatibility such as a markedly reduced inflammatory capacity, and, in addition, have an anti-bacterial and anti-fibrosis effect, which makes them particularly suitable for use as a biomedical material, e.g. for medical devices such as implants or prostheses.
SUMMARY OF THE INVENTION
In a first aspect, the invention relates to a biocompatible alloy comprising, consisting essentially of or consisting of a metal composition selected from the group consisting of Ta- Nb-Ti, Ta-Nb-nTi, Ta-Nb-Ti+X+Y, and Ta-Nb-nTi+mX+kY, wherein n, m, or k = 1-70 atomic % and X, Y = Pt, Zr, Co, Cr, V, Ag, Au, Ni, Hf, Mo, W, Al, Mn, Cu, Li, rare earths, Fe, or Ir.
In a second aspect, the invention relates to a material composed of or coated with the inventive biocompatible alloy.
In a third aspect, the invention relates to a material composed of or coated with the inventive biocompatible alloy for use as a material with anti-bacterial and/or anti-inflammatory effects.
In a fourth aspect, the invention relates to a material composed of or coated with the inventive biocompatible alloy for use as a material with an anti-fibrotic effect.
In a fifth aspect, the invention relates to a material composed of or coated with the inventive biocompatible alloy for use as a material for prostheses with reduced or no septic prosthesis loosening.
In a sixth aspect, the present invention relates to a coating comprising the inventive biocompatible alloy.
In a seventh aspect, the invention relates to the use of the inventive biocompatible alloy as a coating.
In an eighth aspect, the invention relates to the inventive biocompatible alloy for use as coating or substrate/bulk material with anti-bacterial and/or anti-inflammatory effects.
In a ninth aspect, the present invention relates to the inventive biocompatible alloy for use as coating or substrate/bulk material with an anti-fibrotic effect.
In a tenth aspect, the present invention relates to the inventive biocompatible alloy for use as coating or substrate/bulk material for prostheses with reduced or no septic prosthesis loosening.
In an eleventh aspect, the present invention relates to the use of the inventive biocompatible alloy as coating or substrate/bulk material with anti-bacterial and/or anti-inflammatory effects.
In a twelfth aspect, the present invention relates to the use of the inventive biocompatible alloy as coating or substrate/bulk material with an anti-fibrotic effect.
In a thirteenth aspect, the present invention relates to the use of the inventive biocompatible alloy as coating or substrate/bulk material for prostheses with reduced or no septic prosthesis loosening.
In a fourteenth aspect, the present invention relates to the use of a material composed of or coated with the inventive biocompatible alloy as a material with anti-bacterial and/or antiinflammatory effects.
In a fifteenth aspect, the present invention relates to the use of a material composed of or coated with the inventive biocompatible alloy as a material with an anti-fibrotic effect.
In a sixteenth aspect, the present invention relates to the use of a material composed of or coated with the inventive biocompatible alloy as a material for prostheses with reduced or no septic prosthesis loosening.
In a seventeenth aspect, the present invention relates to a method for the manufacture of an inventive biocompatible alloy, wherein the process comprises melting/remelting or mechanical milling/alloying elemental Ti, Nb, Ta, and/or hydrides of the respective elements as well as partially or entirely pre-alloyed starting materials in the respective relative amounts in an arc-melting device under an Ar atmosphere, in a powder mill/attrition device under inert gas atmosphere and/or subsequent sintering processes and/or fabricated by additive or generative manufacturing methods.
In an eighteenth aspect, the present invention relates to a method for treating bone damages comprising implanting a material composed of or coated with the inventive biocompatible alloy.
In a nineteenth aspect, the present invention relates to a method for treating septic prosthesis loosening comprising implanting a prosthesis composed of or coated with the inventive biocompatible alloy.
This summary of the invention does not necessarily describe all features and/or all aspects of the present invention. Other embodiments will become apparent from a review of the ensuing detailed description.
DETAILED DESCRIPTION
Definitions
In the following the invention is described in more detail with reference to the Figures. The described specific embodiments of the invention, examples, or results are, however, intended for illustration only and should not be construed to limit the scope of the invention as indicated by the appended claims in any way.
It is to be understood that this invention is not limited to the particular methodology, protocols, and reagents described herein as these may vary It is also to be understood that the terminology used herein is to describe particular embodiments only, and is not intended to limit the scope of the present invention which will be limited only by the appended claims. Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art.
Each of the documents cited in this specification (including all patents, patent applications, scientific publications, manufacturer's specifications, instructions, etc ), whether supra or infra, is hereby incorporated by reference in its entirety. In the event of a conflict between the definitions or teachings of such incorporated references and definitions or teachings recited in the present specification, the text of the present specification takes precedence.
The term “comprising” or variations thereof such as “comprise(s)” according to the present invention (especially in the context of the claims) is to be construed as an open-ended term or non-exclusive inclusion, respectively (i.e., meaning "including, but not limited to,") unless otherwise noted.
The term "comprising" shall encompass and include the more restrictive terms "consisting essentially of' or "comprising substantially", and "consisting of'.
In the case of chemical compounds or compositions, the terms "consisting essentially of' or "comprising substantially" mean that specific further components can be present, namely those not materially affecting the essential characteristics of the compound or composition, e.g., unavoidable impurities.
The terms “a”, “an”, and “the” as used herein in the context of describing the invention (especially in the context of the claims) should be read and understood to include at least one
element or component, respectively, and are to be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context.
In addition, unless expressly stated to the contrary, the term “or” refers to an inclusive “or” and not to an exclusive “or” (i.e., meaning “and/or”).
All numeric values are herein assumed to be modified by the term “about”, whether or not explicitly indicated. Recitation of ranges of values herein is merely intended to serve as a shorthand method of referring individually to each separate value falling within the range, unless otherwise indicated herein, and each separate value is incorporated into the specification as if it were individually recited herein.
The use of terms “for example”, “e g ”, “such as”, or variations thereof is intended merely to better illuminate the invention and does not pose a limitation on the scope of the invention unless otherwise claimed. These terms should be interpreted to mean “but not limited to” or “without limitation”.
The term “biocompatible”, as used herein, refers to the ability of a biomaterial to perform its desired function for medical therapy, without eliciting any undesirable local or systemic effects in the recipient or beneficiary of that therapy, but generating the most appropriate beneficial cellular or tissue response in that specific situation, and optimizing the clinically relevant performance of that therapy.
The term “alloy”, as used herein, refers to a mixture of chemical elements of which at least one is a metal. Unlike chemical compounds with metallic bases, an alloy will retain all the properties of a metal in the resulting material, such as electrical conductivity, ductility, opacity, and luster, but may have properties that differ from those of the pure metals, such as increased strength or hardness. In some cases, an alloy may reduce the overall cost of the material while preserving important properties. In other cases, the mixture imparts synergistic properties to the constituent metal elements such as corrosion resistance or mechanical strength. The present inventors found that the alloy as described herein has outstanding anti-bacterial and/or antiinflammatory effects, such as growth-limiting/inhibiting effects on bacteria. They also found that the alloy as described herein has anti-fibrotic effects. When coated on prothesis, the present inventors further found reduced or no septic prothesis loosening over time.
The term “rare earths”, as used herein, refers to the elements Sc, Y, La, Ce, Pr, Nd, Pm, Sm, Eu, Gd, Tb, Dy, Ho, Er, Tm, Yb, and Lu.
The term “atomic percent” (at. %), as used herein, refers to the number of atoms of an element in 100 atoms representative of a substance.
The term “interstitially solvable elements” as used herein, refers to elements that are completely or partially soluble in the metal lattice of an alloy.
The term “equiatomic alloy”, as used herein, refers to an alloy where the metallic elements are present in equal atomic percentages.
The term “medical device”, as used herein, refers to a non-naturally occurring object or artificial object that is used to examine and/or treat a subject, that is inserted or implanted in a subject, or that is applied to a surface of a subject. An implantable device is one intended to be completely imbedded in the body without any structure left outside the body (e.g. an implant or a prothesis). An insertable device is one that is partially imbedded in the body but has a part intended to be external (e g. a catheter or a drain). Medical devices can be intended for shortterm or long-term residence where they are positioned. A hip implant is intended for several years of use, for example. By contrast, a tissue expander may only be needed for a few months, and is removed thereafter. Insertable devices tend to remain in place for shorter times than implantable devices, in part because they come into more contact with microorganisms that can colonize them. The medical devices described herein are composed of or are coated with the biocompatible alloy of the present invention. Said alloy has an anti-bacterial and/or anti-inflammatory effect. Thus, the medical device has a longer life time and can remain longer in the subject’s body. The subject described herein may be a human or an animal. The medical device may be an extracorporeal medical device, an implant, preferably a prothesis, or a catheter.
The term “extracorporeal medical device”, as used herein, refers to device whose function is performed outside the body. Extracorporeal devices are the artificial organs that remain outside the body while treating a patient. Extracorporeal devices are useful, for example, in hemodialysis and cardiac surgery.
The term “implant”, as used herein, refers to an artificial material intended for placement in a human or animal body. In particular, the term “implant”, as used herein, refers to an artificial material implanted in the body to remain there permanently or at least for a longer period of time. The term “implant”, as used herein, can be applied to the entire spectrum of medical devices intended for placement in a human or animal body. The implant is preferably a prosthesis.
The term “prosthesis”, as used herein, refers to a medical device that replaces a missing body part, which may be lost through trauma, disease, or a condition present at birth (congenital disorder). A prosthesis is intended to restore the normal functions of the missing body part. A “prosthesis” can also be designated as prosthetic implant.
Preferably, the prosthesis is an endoprosthesis.
The term “endoprosthesis (from the Greek endo “inside”), as used herein, refers to a joint replacement. It remains permanently in the body and replaces a damaged joint in whole or in part. An endoprosthesis which replaces a damaged joint in whole is designated as total endoprosthesis and an endoprosthesis which replaces a damaged joint in part is designated as partial endoprosthesis. Preferably, the endoprosthesis is a hip joint or a knee joint.
The surgical procedure for replacing the joint with a prosthesis is called arthroplasty.
The term “coating”, as used herein, refers to any layer covering a surface, e g. of a material or article such as medical device. In the present invention, the inventive biocompatible alloy is used for coating or as coating. The biocompatible alloy to be coated can be in form of a liquid, a paste, a semi-solid, or a solid. It is preferred that the coating completely and/or uniformly covers the surface of the material to be coated. The coating has preferably a thickness of between 1 nm and 1000 pm, preferably 40 nm and 50 pm, more preferably between 0.1 pm and 10 pm and most preferably between 0.5 pm and 5 pm The coating can be achieved by dip coating and/or spray coating, as well as thin- film technology processes (such as CVD, PVD) and powder pack cementation.
Medical devices, such as implants or prostheses, are widely used to replace damaged tissues or to treat various diseases. However, they may cause microbial infections such as bacterial or fungal infections, when introduced into the body of a subject.
The inventive alloy as described herein has an anti-microbial effect or activity, specifically a growth-limiting/inhibiting effect on microorganisms. The microorganisms are preferably selected from the group consisting of bacteria, viruses, archaea, fungi and protists.
The term “anti-microbial effect or activity” of a material, as used herein, is associated with the property of the material to kill or inhibit microorganisms. Particularly, the inhibition of microorganisms is achieved by slow down the rate of growth of the microorganisms. The term “antimicrobial activity or effect”, as used herein, can also be defined as a collective term for all active principles that inhibit the growth of microorganisms, prevent the formation of colonies of microorganisms, and may destroy microorganisms.
The material may be a material composed of or coated with the inventive alloy as described herein.
The inventive alloy as described herein has an anti-bacterial effect or activity, specifically a growth-limiting/inhibiting effect or activity on bacteria.
The term “anti-bacterial effect or activity” of a material, as used herein, is associated with the property of the material to kill or inhibit bacteria. Particularly, the inhibition of bacteria is achieved by slow down the rate of growth of the bacteria. The term “anti-bacterial activity or
effect”, as used herein, can also be defined as a collective term for all active principles that inhibit the growth of bacteria, prevent the formation of colonies of bacteria, and may destroy bacteria.
The material may be a material composed of or coated with the inventive alloy as described herein.
The growth of microorganisms such as bacteria may be inhibited by the material composed of or coated with the inventive alloy by at least 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 98% or 99%, or by 100% as compared to a material not being composed or coated with the inventive alloy. Preferably, bacteria growth is inhibited by at least 20%. More preferably, bacteria growth is inhibited by at least 40%. Even more preferably, bacteria growth is inhibited by at least 60%. Most preferably, bacteria growth is inhibited by at least 90% or of even 100%.
As mentioned above, medical devices, such as implants or prostheses, are widely used to replace damaged tissues or to treat various diseases. However, besides the risk of microbial infections such as bacterial or fungal infections, an inflammatory response usually occurs. Here, recent progress in the field of anti-inflammatory biomaterials is described. The inventive alloy as disclosed herein prevents or does not cause an inflammatory response in the body of a subject.
The term “anti-inflammatory effect or activity” of a material, as used herein, is associated with the property of the material to reduce inflammation (such as redness, swelling, and/or pain) in the body. An anti-inflammatory material is able to block certain substances in the body that cause inflammation or that does not cause inflammation due to its own composition/structure. The material may be a material composed of or coated with the inventive alloy as described herein.
As mentioned above, medical devices, such as implants or prostheses, are widely used to replace damaged tissues or to treat various diseases. However, they may lead to an increased fibrosis when introduced into the body of a subject. The increased fibrosis is associated with a subsequent restriction of the range of motion of the affected medical devices, e g. joints.
In addition to the anti-microbial such as anti-bacterial effect and the anti-inflammatory effect, the inventive alloy as described herein has an anti-fibrotic effect. In this way, movement restrictions after implantation of a medical device can be prevented.
Fibrotic and scarring processes are mainly derived by the proliferation of fibroblasts and exuberant extracellular matrix (ECM) expression. The term “anti-fibrotic effect or activity” of a
material, as used herein, is associated with the property to prevent such fibrotic and scarring processes in the body.
The material may be a material composed of or coated with the inventive alloy as described herein.
Due to the use of the inventive alloy as described herein, as prosthesis coating, for example, a prothesis loosening can be reduced or inhibited.
The prosthesis loosening can be reduced or inhibited with the inventive alloy as a coating by at least 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 98% or 99%, or by 100% as compared to a prosthesis not coated with the inventive alloy. Preferably, prosthesis loosening is inhibited by at least 20%. More preferably, prosthesis loosening is inhibited by at least 40%. Even more preferably, prosthesis loosening is inhibited by at least 60%. Most preferably, prosthesis loosening is inhibited by at least 90% or of even 100%.
The term “substrate/bulk material”, as used herein, refers to the alloy and or the coating in a compact state after processing.
No language in this specification should be construed as indicating any non claimed element as essential to the practice of the invention.
Embodiments
The present invention is based on the surprising finding that novel Ta-Nb-Ti alloys show superior biocompatibility such as a markedly reduced inflammatory capacity, and, in addition, have an anti-bacterial and anti-fibrosis effect, which makes them particularly suitable for use as a biomedical material, e.g. for implants or prostheses.
Thus, in a first aspect, the present invention relates to a biocompatible alloy compris- ing/consisting essentially of/consisting of a metal composition selected from the group consisting of Ta-Nb-Ti, Ta-Nb-nTi, Ta-Nb-Ti+X+Y, and Ta-Nb-nTi+mX+kY, wherein n, m, or k = 1-70 atomic % and X, Y = Pt, Zr, Co, Cr, V, Ag, Au, Ni, Hf, Mo, W, Al, Mn, Cu, Li, rare earths, Fe, or Ir. It is preferred that n, m, or k = 1-50 atomic %. It is more preferred that n, m, or k = 1- 40 atomic %. It is even more preferred that n, m, or k = 1-30 atomic %. It is still even more preferred that n, m, or k = 1-20 atomic %.
In one embodiment of the present invention, the biocompatible alloy may be selected from the group consisting of Ta-Nb-Ti, Ta-Nb-lOTi, Ta-Nb-50Ti, Ta-Nb-70Ti, Ta-Nb-Ti- 6.2Co, Ta-Nb-Ti-6.2Cr, Ta-Nb-Ti-2.2Co-2.2Cr, Ta-Nb-Ti-Hf, Hf-Nb-Ti, Ta-Nb-Ti-Zr, Hf-Nb- Ti-Zr, and Ta-Nb-Ti-Hf-Zr, wherein the relative amounts of each element preferably vary by no more than ± 15 atomic %, e.g. ± 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 atomic %.
In another embodiment of the present invention, the biocompatible alloy additionally comprises one or more compounds or combinations selected from the group consisting of oxides, nitrides, borides, silicides, hydrides, and carbides, in particular AI2O3, ZrCh, TiCh, Y2O3, HfCh, TiN, Cas[OH |(PO4)3], TiC, TilU and OXINIUM®(a Zr-Nb alloy commercially available from Smith & Nephew pic, London, UK).
In yet another embodiment of the present invention, the biocompatible alloy additionally comprises one or more interstitially solvable elements selected from the group consisting of C, O, N, H, and B; wherein the relative amounts of each element in each particular phase are maximum 2 atomic %, e.g. 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, or 2 atomic %.
The biocompatible alloys of the present invention have anti-bacterial and/or anti-inflammatory and/or anti-fibrotic effects and/or reduce or prevent septic prosthesis loosening.
The anti-bacterial effects preferably comprise a growth-limiting/inhibiting effect on bacteria.
The anti-inflammatory effects comprise reducing or preventing inflammation in the body or body parts, resulting, e.g., in redness, swelling, and pain.
The anti-fibrotic effects comprise reducing or preventing fibrosis, also known as fibrotic scarring, i.e., a pathological wound healing in which connective tissue replaces normal parenchymal tissue to the extent that it goes unchecked, leading to considerable tissue remodeling and the formation of permanent scar tissue.
In a second aspect, the present invention relates to a material or an article composed of or coated with the inventive biocompatible alloy.
It is preferred that the coating completely and/or uniformly covers the surface of the material or article to be coated. The coating has preferably a thickness of between 1 nm and 1000 pm, preferably 40 nm and 50 pm, more preferably between 0.1 pm and 10 pm and most preferably between 0.5 pm and 5 pm. The coating can be achieved by dip coating and/or spray coating, as well as thin-film technology processes (such as CVD, PVD) and powder pack cementation.
In a third aspect, the invention relates to a material or an article composed of or coated with the inventive biocompatible alloy for use as a material or an article with anti-bacterial and/or anti-inflammatory effects. Preferably, the anti-bacterial effects comprise a growth-limiting/inhibiting effect on bacteria.
The growth of bacteria may be inhibited by the material or article composed of or coated with the inventive alloy by at least 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 98% or 99%, or by 100% as compared to a material or an article not being composed or
coated with the inventive alloy. Preferably, bacteria growth is inhibited by at least 20%. More preferably, bacteria growth is inhibited by at least 40%. Even more preferably, bacteria growth is inhibited by at least 60%. Most preferably, bacteria growth is inhibited by at least 90% or of even 100%.
In a fourth aspect, the invention relates to a material or article composed of or coated with the inventive biocompatible alloy for use as a material or article with an anti-fibrotic effect.
Thus, the material or article composed of or coated with the inventive biocompatible alloy has anti-bacterial and/or anti-inflammatory and/or anti-fibrotic effects.
In a fifth aspect, the invention relates to a material or article composed of or coated with the inventive biocompatible alloy for use as a material or article for prostheses with reduced or no septic prosthesis loosening.
More preferably, the material or article composed of or coated with the inventive biocompatible alloy as described above is a medical device, e g , an implant (e g., a dental implant), a prosthesis (e.g., a hip or knee prosthesis), a tool, a bone pin, a bone screw, a bone plate, or a container. When the material or article is a prosthesis the anti-bacterial and anti-fibrotic effects of the inventive alloys reduce or prevent septic prosthesis loosening. The medical profession understands prosthesis loosening to mean that an endoprosthesis (also known as an implant), for example, the components of an artificial hip joint or knee joint, are no longer firmly anchored in the bone. Prosthesis loosening is a phenomenon that occurs in approximately 8% of all implanted joint prostheses within 10 years of installation. This affects approximately 10,000 to 12,000 patients per year worldwide.
In a sixth aspect, the present invention relates a coating comprising the inventive biocompatible alloy.
The coating has preferably a thickness of between 1 nm and 1000 pm, preferably 40 nm and 50 pm, more preferably between 0.1 pm and 10 pm and most preferably between 0.5 pm and 5 pm. The coating can be achieved by dip coating and/or spray coating, as well as thin-film technology processes (such as CVD, PVD) and powder pack cementation.
The coating may be applied onto a material (e g. medical device) or article.
In a seventh aspect, the present invention relates to the use of the inventive biocompatible alloy as a coating or substrate/bulk material.
The biocompatible alloy to be coated can be in form of a liquid, a paste, a semi-solid, or a solid. It is preferred that the coating completely and/or uniformly covers the surface of the material to be coated. The coating has preferably a thickness of between 1 nm and 1000 pm, preferably 40 nm and 50 pm, more preferably between 0.1 pm and 10 pm and most preferably between
0.5 pm and 5 m. The coating can be achieved by dip coating and/or spray coating, as well as thin-film technology processes (such as CVD, PVD) and powder pack cementation.
The coating may be applied onto a material (e g. medical device) or article.
In an eighth aspect, the invention relates to the inventive biocompatible alloy for use as coating or substrate/bulk material with anti-bacterial and/or anti-inflammatory effects. Preferably, the anti-bacterial effects comprise a growth-limiting/inhibiting effect on bacteria.
In a ninth aspect, the present invention relates to the inventive biocompatible alloy for use as coating or substrate/bulk material with an anti-fibrotic effect.
In a tenth aspect, the present invention relates to the inventive biocompatible alloy for use as coating or substrate/bulk material for prostheses with reduced or no septic prosthesis loosening.
In an eleventh aspect, the present invention relates to the use of the inventive biocompatible alloy as coating or substrate/bulk material with anti-bacterial and/or anti-inflammatory effects. Preferably, the anti-bacterial effects comprise a growth-limiting/inhibiting effect on bacteria.
In a twelfth aspect, the present invention relates to the use of the inventive biocompatible alloy as coating or substrate/bulk material with an anti-fibrotic effect.
In a thirteenth aspect, the present invention relates to the use of the inventive biocompatible alloy as coating or substrate/bulk material for prostheses with reduced or no septic prosthesis loosening.
In a fourteenth aspect, the present invention relates to the use of a material or an article composed of or coated with the inventive biocompatible alloy as a material or an article with anti-bacterial and/or anti-inflammatory effects. Preferably, the anti-bacterial effects comprise a growth-limiting/inhibiting effect on bacteria.
In a fifteenth aspect, the present invention relates to the use of a material or an article composed of or coated with the inventive biocompatible alloy as a material or an article with an anti-fibrotic effect.
In a sixteenth aspect, the present invention relates to the use of a material or an article composed of or coated with the inventive biocompatible alloy as a material or an article for prostheses with reduced or no septic prosthesis loosening.
More preferably, the material or article composed of or coated with the inventive biocompatible alloy as described above is a medical device, e.g., an implant (e.g., a dental implant), a prosthesis (e.g., a hip or knee prosthesis), a tool, a bone pin, a bone screw, a bone plate, or a container.
Thus, the material or article composed of or coated with the inventive biocompatible alloy has anti-bacterial and/or anti-inflammatory and/or anti-fibrotic effects. When the material or article is a prosthesis the anti-bacterial and anti-fibrotic effects of the inventive alloys reduce or prevent septic prosthesis loosening. The medical profession understands prosthesis loosening to mean that an endoprosthesis (also known as an implant), for example, the components of an artificial hip joint or knee joint, are no longer firmly anchored in the bone. Prosthesis loosening is a phenomenon that occurs in approximately 8% of all implanted joint prostheses within 10 years of installation. This affects approximately 10,000 to 12,000 patients per year worldwide.
In a seventeenth aspect, the present invention relates to a method for the manufacture of the inventive biocompatible alloy, wherein the process comprises melting/remelting or mechanical milling/alloying elemental Ti, Nb, Ta, and/or hydrides of the respective elements as well as partially or entirely pre-alloyed starting materials in the respective relative amounts in an arc-melting device under an Ar atmosphere, in a powder mill/attrition device under inert gas atmosphere and/or subsequent sintering processes and/or fabricated by additive or generative manufacturing methods.
As to the preferred embodiments of the inventive biocompatible alloy, it is referred to the first aspect of the present invention.
In one embodiment of the inventive method for manufacturing an inventive biocompatible alloy a subsequent heat treatment is used, e g. to ensure sufficient homogeneity of the alloy.
In an eighteenth aspect, the present invention relates to a method for treating bone damages comprising implanting a material composed of or coated with the inventive biocompatible alloy.
In a nineteenth aspect, the present invention relates to a method for treating septic prosthesis loosening comprising implanting a prosthesis composed of or coated with the inventive biocompatible alloy.
All uses described above may be in vitro or in vivo uses.
BRIEF DESCRIPTION OF THE FIGURES
The following Figures are merely illustrative of the present invention and should not be construed to limit the scope of the invention as indicated by the appended claims in any way.
FIGURE 1 shows the calculation of nucleus to cytoplasm ratio for the tested alloys for validation of the osteoblast attachment to alloy surfaces.
FIGURE 2 shows the expression of inflammatory and fibrosis marker genes by monocytes incubated on the novel biocompatible alloy Ta-Nb-Ti, compared to standard implant materials data and elemental Ta and Nb.
FIGURE 3 shows the anti-bacterial effects of the novel biocompatible Ta-Nb-Ti alloy in comparison to the pure components of the alloy and other alloys used as biomaterials.
EXAMPLE
The example given below is for illustrative purposes only and does not limit the invention described above in any way.
Production, preparation, and analysis of substrate materials
For sample production of an equiatomic Ta-Nb-Ti alloy as an example of an inventive alloy, high purity elemental chips or flakes of Ta (99 9%), Nb (99.9%), and Ti (99.6%) were used as starting materials and were carefully weighed. The alloying process was carried out in a conventional arc-melting device under Ar atmosphere. Each sample was as re-melted five times to ensure sufficient homogeneity.
Afterward, the produced oblong-shaped (due to the use of an elongated mold) melted product was cut into 2mm thick slices by means of electric discharge machining (EDM). One slice was used for microstructural analysis and thus metallographically prepared (ground with SiC paper to 1000 grit, polished using 3 pm and 1 pm diamond suspension, and finished using colloidal silica suspension subsequently) afterward. The remaining slices were cleaned from the EDM-burr and ground to a defined grit size of 1200.
To identify the phases present, X-ray diffraction analysis (XRD) was performed on a X’Pert Pro (PANalytical, Almelo, The Netherlands), using Co Ka radiation. Microstructural observations were carried out using scanning electron microscopy (ESEM XL30 FEG, FEI, Hillsboro, OR, USA), using back-scattered electron (BSE) imaging with the following setup: Centaurus BSE detector with an acceleration voltage of 25 kV, magnification of lOOx and a working distance of 11.4 mm.
To determine the elemental distribution and the chemical composition of the alloy, (Si(Li))-detector energy-dispersive X-ray spectroscopy (EDS) analysis equipped with Genesis software (ED AX, Mahwah, NJ, USA) was conducted.
The surface roughness of the samples was analyzed by using a confocal microscope (psurf expert, NanoFocus AG, Oberhausen, Germany) on a surface area of 322 x 321 pm, using a 20x magnification objective with a lateral (x, y) measuring range of 800 pm.
In addition, the contact angles of the surfaces were determined using an optical contact angle and drop contour analyzer (OCA 20, DataPhysics Instruments GmbH, Filderstadt, Germany) and the corresponding software (SCA 20, DataPhysics Instruments GmbH, Filderstadt, Germany).
To characterize the hardness of the alloy produced, microhardness analysis was carried out using 20 HVO.1 indents in a square grid across the entire sample surface, using an automatic hardness tester VH3300 (Wilson/Buehler, Esslingen, Germany).
Furthermore, to examine and evaluate the biocompatibility of the alloy Ta-Nb-Ti, cell cultivation experiments were carried out on the surface of the specimens and compared to state- of-the-art biomaterials, such as wrought alloy Co-28Cr-6Mo or alloy Ti-6A1-4V, as well as to samples of pure Ta, Nb, and Ti.
Osteoblast (SaQs Cells) attachment assay
SaOs-2 cells were seeded with a cell number of 0.3 x 105 inlOO uL for 2 h on platelets of standard implant alloys (Co-28Cr-6Mo, Ti-6A1-4V, and pure Ti), elemental Ta and Nb, and novel biocompatible alloy Ta-Nb-Ti to let the cells attach to the surface. Afterward, 1 mL DMEM (Dulbecco Modified Eagle Medium) culture medium with the addition of 10% FCS (fetal calf serum) and 1% penicillin/ streptomycin was pipetted into each well to cover the platelets with cells.
On the following day, the cells were fixed with 4% formaldehyde and washed three times with PBS (phosphate-buffered saline).
Subsequently, the samples were incubated with 200 pL of PBS with Phalloidin Alexa Fluor 488 (1 : 100) and DAPI (4F,6-Diamidino-2-phenylindol) (1:1000) in the dark for 15 min (room temperature, RT). Excess staining solution was removed by washing three times with PBS. The samples were stored at 4 °C in the dark until further use.
Imaging was performed with a Zeiss fluorescence microscope (Axio Observer.Zl, Zeiss, Jena, Germany) at 63 Ox magnification. Fluorescence was detected at the wavelengths 488 nm (Phalloidin green) and 454 nm (DAPI blue). Four images were taken of each sample. For evaluation, the area of one cell (green fluorescence) was divided by the size of the nucleus (blue fluorescence) using ImageJ.
FIGURE 1 shows the calculation of nucleus to cytoplasm ratio for the tested alloys (Mean ± SEM standard error of mean ), N = 3, p = 0.4 using one-way ANOVA (analysis of variance)) fora validation of the cell attachment to alloy surfaces.
Good colonization and no negative effects were observed compared to the reference samples.
Monocyte inflammatory reaction test
Mona-mac-6 cells (MM6) are a human acute monocytic leukemia derived cell line. These cells were cultured at a density 0.5 x 106 in 100 pL on the different alloy specimens for 24 h. Subsequently, the cells were lysed using TRIZol, and RNA (ribonucleic acid) was isolated for quantitative RT-PCR (reverse transcription polymerase chain reaction).
RNA extraction, cDNA synthesis, real-time RT-PCR
Total RNA was extracted from cells using TRIZol reagent (Invitrogen, Thermo Fisher Scientific). Thus, 1 ng of total RNA from each sample was reverse transcribed using the High- Capacity cDNA (complementary deoxyribonucleic acid) Reverse Transcription Kit (Applied Biosystems) using random primers. Quantitative PCR (polymerase chain reaction) was performed with SYBR green using Applied Biosystems™ and Quantstudio 6 (Thermo Fisher Scientific). At an annealing temperature of 60 °C primers for human interleukin- 1 P (hIL-ip), human tumor necrosis factor-oc (hTNF-a), human interleukin-6 (hIL-6), and human glyceralde- hyde-3 -phosphate dehydrogenase (hGAPDH) were used. Absolute quantification was carried out using standard curves. Target gene expression was normalized to GAPDH.
FiGURE 2 shows the expression of inflammatory marker genes (IL-6, IL-ip, TNF-ot) and fibrosis marker genes (TGF-P, fibronectin) by monocytes incubated on novel biocompatible alloy Ta-Nb-Ti, compared to standard implant materials data and elemental Ta and Nb. Quantitative RT-PCR results (a) IL-6 expression on tested implant materials, (b) IL-ip expression, (c) TNF-oc expression, (d) TGF-P expression and (e) Fibronectin expression (N = 5). GAPDH was used as housekeeping. The values are given as mean with SEM and were analyzed for statistical significance using a one-way ANOVA with Dunn's post-hoc test. * p <0.05; ** p < 0.01. With regard to the fibrosis markers, the novel alloy Ta-Nb-Ti is comparable with the reference samples and thus showed no negative influence of the alloy composition. With regard to the inflammation markers, however, the novel alloy Ta-Nb-Ti showed a significantly lower value than the reference samples, which indicates an anti-inflammatory effect of the alloy.
Tests for anti-bacterial effect
Staphylococcus capitis adhesion test
S. capitis (DSM 20326 (from Leibniz Institute DSMZ) was cultivated overnight in tryptic Soy Broth (TSB). The following day 1 ml TSB was inoculated with a 1 : 100 dilution of the S. captitis overnight culture with an optical density of 1 at 600 nm (OD600) for 24 hours. The medium was removed and washed twice with PBS and subsequently fixed with 4 % paraformaldehyde for 30 min at room temperature. The samples were incubated with 1 ml PBS and 4', 6- diamidine-2-phenylindole (DAPI 1 : 1000) to visualize the adhering bacteria on the surface. The
amount of adhering bacteria was quantified in 630x magnification microscopic pictures (Zeiss fluorescence microscope Axio Observer.Zl, Jena, Germany). The fluorescence of the (DAPI) was excited by a wavelength of 454 nm. Pictures from five different areas from each sample were taken and evaluated by counting the amount of bacteria with ImageJ software.
Antibacterial capacity
The key step in biofilm formation on endoprosthetic implant materials is the adhesion of pathogens to the respective material. To test the bacterial adhesion to the novel alloys the samples were incubated for 24 hours with S. capitis. To quantify the amount of adhering bacteria DAPI was used to visualize the DNA of the bacteria, and then the bacteria were counted using ImageJ (data not shown).
FIGURE 3 shows the anti-bacterial effects of the novel biocompatible Ta-Nb-Ti alloy in comparison to the pure components of the alloy (Ta, Nb, and Ti) and other alloys used as biomaterials (Ti-6A1-4V, CoCrMo). S. capitis = Staphylococcus capitis, E coli = Escherichia coli. It can be seen that the number of bacteria on the novel Ti-Nb-Ti alloy was many times lower than the number on all other reference samples.
Statistical analysis of the biocompatibility experiments
If not stated otherwise, the data are presented as mean ± standard deviation (SM. The Friedman test was applied to test for statistical significance. The level of significance was set at p < 0.05 for all statistical tests. Statistical analysis was performed using GraphPad Prism (Version 7, GraphPad Software, San Diego, CA, USA).
Results and discussion
To test the usability of the novel alloys of the present invention as an endoprosthetic implant material in an intraosseous application, human osteosarcoma cells (SaOs-2) were incubated on the novel sample alloy Ta-Nb-Ti, as well as on reference elements Ta and Nb and samples, which are already used as implant material (Co-28Cr-6Mo, Ti-6A1-4V, and pure Ti). To evaluate the interaction of the osteoblast-like cells with the different materials, the attachment and spreading of these cells on the surfaces were investigated. Phalloidin was used to visualize the cytoskeleton. Phalloidin can penetrate the cells and binds with high selectivity to the F-actin of the cytoskeleton. For imaging, the Phalloidin is fluorescently labeled with Alexa Fluor 488, which stains the cytoskeleton of the cell green. There is no difference in the number of osteoblasts attached to the different surfaces. Furthermore, the ratio between nucleus and cytoplasm was evaluated to compare the attachment behavior of the cells. Again, there was no difference observed between the alloys tested, indicating no negative effect on the osteoblasts (FIGURE 1).
A reaction towards a foreign material in the human body is an unavoidable process that takes place whenever any material is implanted. This reaction is mostly inflammatory (e.g., IL- 6 and TNF-a) and can develop into a fibrotic response (TGF-P and fibronectin) over time. Therefore, in a subsequent step, the inflammatory potential of the novel alloys was tested using a monocyclic cell line (MM6). These cells were incubated for 24 h on the different platelets and the reaction of these cells towards either inflammation (FIGURE 2 a-c) or fibrosis marker genes (FIGURE 2 d,e) was investigated using qRT-PCR. No significant differences between Co-28Cr-61Mo, Ti-6A1-4V, pure Ti, Ta, and Nb were observed.
However, a significantly reduced expression of IL-6 (about 20-fold, p = 0.006), IL-1 (about 3-fold, p = 0.007), and TNF alpha (about 2-told, p = 0.04) was observed comparing alloy Ta-Nb-Ti to the other samples examined. Especially, in comparison to pure Ti or Ti-6A1-4V, alloy Ta-Nb-Ti showed a markedly reduced inflammatory capacity The most surprising result is that alloy Ta-Nb-Ti appears to be more resistant to inflammation in comparison with the respective elements Ta, Nb, and Ti. No changes in expression were observed for fibrosis markers demonstrating an anti-fibrotic effect.
While certain representative embodiments and details have been shown to illustrate the present invention, it will be apparent to those skilled in this art that various changes and modifications can be made and that, within the scope of the appended claims, the invention may be practiced otherwise than as specifically described and claimed.
Claims
CLAIMS A biocompatible alloy comprising/consi sting essentially of/consisting of a metal composition selected from the group consisting of: Ta-Nb-Ti, Ta-Nb-nTi, Ta-Nb-Ti+X+Y, and Ta-Nb-nTi+mX+kY, wherein n, m, or k = 1-70 atomic % and X, Y = Pt, Zr, Co, Cr, V, Ag, Au, Ni, Hf, Mo, W, Al, Mn, Cu, Li, rare earths, Fe, or Ir. The biocompatible alloy according to claim 1, wherein the alloy is selected from the group consisting of: Ta-Nb-Ti, Ta-Nb-lOTi, Ta-Nb-50Ti, Ta-Nb-70Ti, Ta-Nb-Ti- 6.2Co, Ta-Nb-Ti-6.2Cr, Ta-Nb-Ti-2.2Co-2.2Cr, Ta-Nb-Ti-Hf, Hf-Nb-Ti, Ta-Nb-Ti-Zr, Hf-Nb-Ti-Zr, and Ta-Nb-Ti-Hf-Zr, wherein the relative amounts of each element preferably vary by no more than ± 15 atomic % The biocompatible alloy according to claims 1 or 2, wherein the alloy additionally comprises one or more compounds or combinations selected from the group consisting of oxides, nitrides, borides, silicides, hydrides and carbides, in particular AI2O3, ZrO2, TiO2, Y2O3, HfO2, TiN, Ca5[OH |(PO4)3], TiC, TiH2 and OXINIUM®. The biocompatible alloy according to any one of claims 1 to 3, wherein the alloy additionally comprises one or more interstitially solvable elements selected from the group consisting of C, O, N, H, and B; and wherein the relative amounts of each element in each particular phase are maximum 2 atomic %. A material composed of or coated with a biocompatible alloy according to any one of claims 1 to 4. The material of claim 5, wherein it is a medical device, preferably an implant, more preferably a prosthesis, a tool, or a container. A material according to claim 5 for use as a material with anti-bacterial and/or antiinflammatory effects.
The material for use according to claim 7, wherein the material has a growth-limit- ing/inhibiting effect on bacteria. A material according to claim 5 for use as a material with an anti-fibrotic effect. A material according to claim 5 for use as a material for prostheses with reduced or no septic prosthesis loosening. The material for use according to any one of claims 7 to 11, wherein the material is a medical device, preferably an implant, more preferably a prosthesis, a tool, or a container. A coating comprising the biocompatible alloy according to any one of claims 1 to 4. Use of the biocompatible alloy according to any one of claims 1 to 4 as a coating. A biocompatible alloy according to any one of claims 1 to 4 for use as coating or sub- strate/bulk material with anti-bacterial and/or anti-inflammatory effects. The biocompatible alloy for use according to claim 14, wherein the alloy has a growth- limiting/inhibiting effect on bacteria. A biocompatible alloy according to any one of claims 1 to 4 for use as coating or sub- strate/bulk material with an anti-fibrotic effect. A biocompatible alloy according to any one of claims 1 to 4 for use as coating or sub- strate/bulk material for prostheses with reduced or no septic prosthesis loosening. Use of a biocompatible alloy according to any one of claims 1 to 4 as coating or sub- strate/bulk material with anti-bacterial and/or anti-inflammatory effects. The use according to claim 18, wherein the alloy has a growth-limiting/inhibiting effect on bacteria.
Use of a biocompatible alloy according to any one of claims 1 to 4 as coating or sub- strate/bulk material with an anti-fibrotic effect. Use of a biocompatible alloy according to any one of claims 1 to 4 as coating or sub- strate/bulk material for prostheses with reduced or no septic prosthesis loosening. Use of a material according to claim 5 as a material with anti-bacterial and/or anti-inflammatory effects. The use according to claim 22, wherein the material has a growth-limiting/inhibiting effect on bacteria. Use of a material according to claim 5 as a material with an anti-fibrotic effect. Use of a material according to claim 5 as a material for prostheses with reduced or no septic prosthesis loosening. The use according to any one of claims 22 to 25, wherein the material is a medical device, preferably an implant, more preferably a prosthesis, a tool, or a container. A method for the manufacture of a biocompatible alloy according to claims 1 to 4, wherein the process comprises melting/remelting or mechanical milling/alloying of elemental Ti, Nb, Ta, and/or hydrides of the respective elements as well as partially or entirely pre-alloyed starting materials in the respective relative amounts in an arc-melting device under an Ar atmosphere, in a powder mill/attrition device under inert gas atmosphere and/or subsequent sintering processes and/or fabricated by additive or generative manufacturing methods. The methods according to claim 27, wherein a subsequent heat treatment is used, e.g. to ensure sufficient homogeneity of the alloy. A method for treating bone damages comprising implanting a material composed of or coated with a biocompatible alloy according to any one of claims 1 to 4.
A method for treating septic prosthesis loosening comprising implanting a prosthesis composed of or coated with a biocompatible alloy according to any one of claims 1 to
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2022/061886 WO2023213385A1 (en) | 2022-05-03 | 2022-05-03 | Novel biocompatible ta-nb-ti alloys, method for preparing the same, and uses thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2022/061886 WO2023213385A1 (en) | 2022-05-03 | 2022-05-03 | Novel biocompatible ta-nb-ti alloys, method for preparing the same, and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2023213385A1 true WO2023213385A1 (en) | 2023-11-09 |
Family
ID=81940415
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP2022/061886 WO2023213385A1 (en) | 2022-05-03 | 2022-05-03 | Novel biocompatible ta-nb-ti alloys, method for preparing the same, and uses thereof |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2023213385A1 (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100086794A1 (en) * | 2008-09-23 | 2010-04-08 | Susanne Norgren | Titanium-based alloy |
| US20190111482A1 (en) * | 2016-02-08 | 2019-04-18 | Abdelmadjid Djemai | Process for producing a beta-alloy Titanium Niobium Zirconium (TNZ) with a very low modulus of elasticity for biomedical applications and its embodiment by additive manufacturing. |
| WO2020058780A1 (en) * | 2018-08-06 | 2020-03-26 | University Chulalongkorn | Antimicrobial biocompatible metal alloy and manufacture of the same |
-
2022
- 2022-05-03 WO PCT/EP2022/061886 patent/WO2023213385A1/en unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100086794A1 (en) * | 2008-09-23 | 2010-04-08 | Susanne Norgren | Titanium-based alloy |
| US20190111482A1 (en) * | 2016-02-08 | 2019-04-18 | Abdelmadjid Djemai | Process for producing a beta-alloy Titanium Niobium Zirconium (TNZ) with a very low modulus of elasticity for biomedical applications and its embodiment by additive manufacturing. |
| WO2020058780A1 (en) * | 2018-08-06 | 2020-03-26 | University Chulalongkorn | Antimicrobial biocompatible metal alloy and manufacture of the same |
Non-Patent Citations (3)
| Title |
|---|
| LIU JUE ET AL: "Microstructure, mechanical behavior and biocompatibility of powder metallurgy Nb-Ti-Ta alloys as biomedical material", MATERIALS SCIENCE AND ENGINEERING C, ELSEVIER SCIENCE S.A, CH, vol. 71, 20 October 2016 (2016-10-20), pages 512 - 519, XP029848950, ISSN: 0928-4931, DOI: 10.1016/J.MSEC.2016.10.043 * |
| NIINOMI ET AL: "In situ X-ray analysis of mechanism of nonlinear super elastic behavior of Ti-Nb-Ta-Zr system beta-type titanium alloy for biomedical applications", MATERIALS SCIENCE AND ENGINEERING C, ELSEVIER SCIENCE S.A, CH, vol. 28, no. 3, 28 February 2008 (2008-02-28), pages 406 - 413, XP022503039, ISSN: 0928-4931, DOI: 10.1016/J.MSEC.2007.04.028 * |
| SCHNEIDER SERGIO ET AL: "Study of the non-linear stress-strain behavior in Ti-Nb-Zr alloys", MATERIALS RESEARCH, DOT EDITORAÇÃO ELETRÔNICA, SAO CARLOS, BR, vol. 8, no. 4, 1 October 2005 (2005-10-01), pages 435 - 438, XP009152292, ISSN: 1516-1439 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Yang et al. | In vitro and in vivo studies on zinc-hydroxyapatite composites as novel biodegradable metal matrix composite for orthopedic applications | |
| Cordeiro et al. | Development of binary and ternary titanium alloys for dental implants | |
| Sarraf et al. | Silver oxide nanoparticles-decorated tantala nanotubes for enhanced antibacterial activity and osseointegration of Ti6Al4V | |
| Hadjicharalambous et al. | Effect of porosity of alumina and zirconia ceramics toward pre-osteoblast response | |
| Weng et al. | A promising orthopedic implant material with enhanced osteogenic and antibacterial activity: Al2O3-coated aluminum alloy | |
| de Viteri et al. | Structure, tribocorrosion and biocide characterization of Ca, P and I containing TiO2 coatings developed by plasma electrolytic oxidation | |
| Kaliaraj et al. | Biocompatible Zirconia‐Coated 316 stainless steel with anticorrosive behavior for biomedical application | |
| Huang et al. | Cytocompatibility and antibacterial properties of zirconia coatings with different silver contents on titanium | |
| Blawert et al. | Plasma electrolytic oxidation/micro-arc oxidation of magnesium and its alloys | |
| CN107829123B (en) | Aluminum alloy with double-layer coating on surface and preparation method and application thereof | |
| Prakash et al. | On the characterization of functionally graded biomaterial primed through a novel plaster mold casting process | |
| Trincă et al. | New Ti-6Al-2Nb-2Ta-1Mo alloy as implant biomaterial: In vitro corrosion and in vivo osseointegration evaluations | |
| Chen et al. | Endowing biodegradable Zinc implants with dual-function of antibacterial ability and osteogenic activity by micro-addition of Mg and Ag (≤ 0.1 wt.%) | |
| Mat-Baharin et al. | Influence of alloying elements on cellular response and in-vitro corrosion behavior of titanium-molybdenum-chromium alloys for implant materials | |
| Codescu et al. | Zn based hydroxyapatite based coatings deposited on a novel FeMoTaTiZr high entropy alloy used for bone implants | |
| Gong et al. | Fabrication, biodegradation behavior and cytotoxicity of Mg-nanodiamond composites for implant application | |
| Cheng et al. | An in vitro and in vivo comparison of Mg (OH) 2-, MgF 2-and HA-coated Mg in degradation and osteointegration | |
| Kaliaraj et al. | Silver-ceria stabilized zirconia composite coatings on titanium for potential implant applications | |
| Chen et al. | Magnesium-incorporated sol-gel Ta2O5 coating on Ti6Al4V and in vitro biocompatibility | |
| Baslayici et al. | Corrosion behaviour of hydroxyapatite coatings on AZ31 and AZ91 magnesium alloys by plasma spray | |
| Rokkala et al. | Comparative investigation of coating and friction stir processing on Mg-Zn-Dy alloy for improving antibacterial, bioactive and corrosion behaviour | |
| Xiaopeng et al. | Electrochemical corrosion and bioactivity of Ti-Nb-Sn-hydroxyapatite composites fabricated by pulse current activated sintering | |
| Yeung et al. | Nitrogen plasma-implanted nickel titanium alloys for orthopedic use | |
| WO2023213385A1 (en) | Novel biocompatible ta-nb-ti alloys, method for preparing the same, and uses thereof | |
| Sun et al. | Biocompatibility evaluation of novel β-type titanium alloy (Ti–35Nb–7Zr–5Ta) 98 Si 2 in vitro |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22727805 Country of ref document: EP Kind code of ref document: A1 |